The information in this section is intended for visitors outside the United States.
Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need. Safety and efficacy of the following compounds have not been established.
Gilead has helped transform HIV infection from a fatal and debilitating disease into a chronic, manageable condition. Yet new options are needed to improve treatment and care over the course of a lifetime for diverse populations living with HIV around the world. With two million new infections each year, additional prevention options are also needed. And ultimately, a cure is needed to bring an end to the HIV epidemic.
Gilead is committed to the continued discovery and development of HIV therapies for all individuals who live with the disease, regardless of treatment status or age. Our research is focused on the three paradigms: prevention, treatment and cure.
Gilead R&D has helped transform the treatment of chronic hepatitis C infection and help manage chronic hepatitis B infection. Today, the company’s liver disease research focuses on medicines for nonalcoholic steatohepatitis (NASH) in patients with advanced fibrosis and on the long-term suppression of hepatitis B virus.
Despite important scientific progress, cancer remains a leading cause of death worldwide. In both blood cancers and solid tumors, there is an urgent need for new treatments that offer longer remissions, improved survival rates and fewer side effects.
Gilead is exploring novel therapeutics, including combinations of investigational agents, for a range of cancers, with a goal of providing effective new treatment options with favorable safety profiles.
Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders. We believe that combination regimens targeting multiple pathways have the potential to improve patient outcomes
Gilead is collaborating with US Department of Defense, Centers for Disease Control and Prevention and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases. A Gilead investigational agent is currently being studied in Ebola survivors.